To further promote international academic and medical exchange, AP Biosciences invited Dr. Michelle Morris, an oncologist from Sunshine Coast University Private Hospital in Australia, to Taiwan on August 22, 2025. During her visit, Dr. Morris participated in a roundtable discussion with physicians from Taipei Medical University Hospital. She also serves as the Principal Investigator (PI) for AP Biosciences' ongoing AP402 clinical trial in Australia.
Dr. Morris brings extensive clinical and research expertise, having published multiple papers in international journals across breast cancer, prostate cancer, and non-small cell lung cancer, as well as leading numerous clinical trials. AP Biosciences CEO, Dr. Jeng Her, also attended the event, underscoring the company's commitment to expanding its global vision.
The visit included tours of Taipei Medical University Cancer Center, Proton Therapy Center, and Clinical Research Center, along with discussions with Prof. Kang-Yun Lee, Vice President of Taipei Medical University, Prof. Chun-Jen Huang, Director of the Human Research Office, as well as several deputy superintendents and department heads from Taipei Cancer Center, Wan Fang Hospital, and Shuang Ho Hospital. Both sides exchanged insights on the latest research and clinical practices while exploring opportunities for future collaboration.
Dr. Morris's visit not only provided valuable international perspectives but also further strengthened AP Biosciences' collaborative platform with Taiwan's leading medical centers, laying a solid foundation for future multinational medical and clinical research partnerships.
